Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End‐Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects

Two phase I open‐label studies were conducted to investigate the pharmacokinetics (PK), safety, and tolerability of single oral doses of selumetinib in subjects with end‐stage renal disease (ESRD) undergoing hemodialysis and subjects with varying degrees of hepatic impairment; both studies included...

Descripción completa

Detalles Bibliográficos
Autores principales: Dymond, Angela W., Martin, Paul, So, Karen, Huang, Yifan, Severin, Paul, Holmes, Victoria, Mariani, Gabriella, Marbury, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Special Populations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412920/
https://www.ncbi.nlm.nih.gov/pubmed/28019010
http://dx.doi.org/10.1002/jcph.848

Ejemplares similares

Ejemplares similares